KLRB1 and breast cancer: Conversely, prior research has demonstrated that CD161 expression is potentially linked to improved clinical outcomes in lung cancer (Braud et al., 2018), breast cancer (Weng et al., 2022; Huang et al., 2023), oropharyngeal cancer (Wei et al., 2023), and endometrial cancer (Liang et al., 2023).